Metabolon plots fast growth as biomarker biz booms

Metabolon's booming biomarker business has triggered fast expansion at the Durham, NC-based biotech company, and its CEO says that he expects to double the size of its workforce over the next two years. Metabolon has about 100 workers these days, including 37 with PhDs. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.